Researchers at Baylor College of Medicine and Rice University have received a $2.3 million Breakthrough Award from the ...

The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in ...

Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...

Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...

A study from researchers at the University of Michigan and the University of California San Diego has shed light on a previously poorly understood aspect of breast cancer recurrence: how cancer cells ...

The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ ...

Researchers also found that metastasis patterns differed by breast cancer subtype. These findings were presented in a poster at the 2024 SNO Annual Meeting. The researchers analyzed 421 patients with ...

Olema Pharmaceuticals, Inc. (OLMA), a clinical-stage biopharmaceutical company, Monday announced a new clinical trial collaboration ...

Flatiron Health today announced their planned presence at this year’s San Antonio Breast Cancer Symposium (SABCS), including four accepted abstracts for poster presentation and a Flatiron ...

Top Forbes | SHOOK financial advisors and Wall Street investment firms have pledged more than $500,000 toward development of ...

The "Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 10+ ...